RAS突变细胞学不确定甲状腺结节:恶性患病率及主动监测下的行为
这项多中心回顾性队列研究分析了RAS突变细胞学不确定甲状腺结节(ITN)在主动监测(AS)下的生长动力学及手术切除后的组织病理诊断。AS队列共62例患者63个结节,中位随访23个月,19.0%出现生长,5年累积生长发生率28.0%,多数结节稳定;最终手术6个结节中1个(16.7%)为恶性。立即手术队列209个结节中33%为恶性,多数为ATA低危癌。作者认为对所有RAS突变ITN立即手术似为低价值实践,需进一步研究确定适合AS或立即手术的病例。
要点
- RAS突变ITN在AS下多数稳定,5年累积生长发生率为28.0%。
- AS队列最终手术6个结节,仅1个(16.7%)为恶性。
- 立即手术队列209个结节中33%为恶性,其中ATA低危癌占23.9%。
核心结论
- RAS突变ITN在AS下多数随时间保持稳定,切除的RAS突变结节多数为良性,癌症多数为ATA低危。
- 对所有RAS突变ITN立即手术似为低价值实践。
- 需进一步研究以界定最适合AS或立即手术的病例。
研究设计与样本
- 多中心回顾性队列研究,分析两个队列:AS队列为三家机构2010-2023年管理的RAS突变ITN,立即手术队列为两家机构2016-2020年管理的RAS突变ITN。
- AS队列纳入随访≥3个月且至少两次超声扫描者;生长定义为肿瘤体积变化≥72%。
- AS队列共62例患者63个RAS突变ITN;立即手术队列共209个RAS突变ITN。
主要发现
- AS队列诊断时中位直径为1.7 cm(四分位距[IQR] 1.2-2.6)。
- 中位AS期23个月(IQR 9.5-53.5个月)内,63个结节中12个(19.0%)出现生长,累积生长发生率1年为1.9%、3年为23.0%、5年为28.0%。
- 81.0%的结节表现为稳定;最终手术6个结节,其中1个(16.7%)为恶性。
- 立即手术队列209个结节中33%为恶性,其中ATA低危癌23.9%、ATA中危癌7.2%、ATA高危癌1.9%。
- 立即手术队列中位随访6.9年(IQR 4.4-7.1年)内无疾病特异性死亡。
临床怎么用
- 作者认为对所有RAS突变ITN立即手术似为低价值实践。
- 作者指出需进一步研究以帮助界定最适合AS或立即手术的病例。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Genomic profiling is now available for risk stratification of cytologically indeterminate thyroid nodules (ITNs). Mutations in RAS genes (HRAS, NRAS, KRAS) are found in both benign and malignant thyroid nodules, although isolated RAS mutations are rarely associated with aggressive tumors. Because the long-term behavior of RAS-mutant ITNs is not well understood, most undergo immediate surgery. In this multicenter retrospective cohort study, we characterize tumor growth kinetics of RAS-mutant ITNs followed with active surveillance (AS) using serial ultrasound (US) scans and examine the histopathologic diagnoses of those surgically resected. Methods: US and histopathologic data were analyzed retrospectively from two cohorts: (1) RAS-mutant ITNs managed with AS at three institutions (2010-2023) and (2) RAS-mutant ITNs managed with immediate surgery at two institutions (2016-2020). AS cohort subjects had ≥3 months of follow-up and two or more US scans. Cumulative incidence of nodule growth was determined by the Kaplan-Meier method and growth by ≥72% change in tumor volume. Pathological diagnoses for the immediate surgery cohort were analyzed separately. Results: Sixty-two patients with 63 RAS-mutated ITNs under AS had a median diameter of 1.7 cm (interquartile range [IQR] 1.2-2.6) at time of diagnosis. During a median AS period of 23 months (IQR 9.5-53.5 months), growth was observed in 12 of 63 nodules (19.0%), with a cumulative incidence of 1.9% (1 year), 23.0% (3 years), and 28.0% (5 years). Most nodules (81.0%) demonstrated stability. Surgery was ultimately performed in 6 nodules, of which 1 (16.7%) was malignant. In the cohort of 209 RAS-mutant ITNs triaged to immediate surgery, 33% were malignant (23.9% American Thyroid Association [ATA] low-risk cancers, 7.2% ATA intermediate-risk, and 1.9% ATA high-risk. During a median follow-up of 6.9 (IQR 4.4-7.1) years, there were no disease-specific deaths in these patients. Conclusions: We describe the behavior of RAS-mutant ITNs under AS and find that most demonstrate stability over time. Of the resected RAS-mutant nodules, most were benign; of the cancers, most were ATA low-risk. Immediate surgical resection of all RAS-mutant ITNs appears to be a low-value practice. Further research is needed to help define cases most appropriate for AS or immediate surgery.
引用
- Sfreddo HJ, Koh ES, Zhao K, et al. RAS-Mutated Cytologically Indeterminate Thyroid Nodules: Prevalence of Malignancy and Behavior Under Active Surveillance. Thyroid. 2024. PMID: 38407967. doi:10.1089/thy.2023.0544
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。